#USA #New York #Class Action #Levi Korsinsky #Zenas BioPharma

Class Action Notification for Investors of Zenas BioPharma, Inc.

On April 22, 2025, Levi & Korsinsky, LLP, a renowned law firm specializing in securities litigation, announced a significant opportunity for investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO). The firm has filed a class action lawsuit aiming to recover losses for those investors allegedly impacted by securities fraud involving Zenas BioPharma. This action is particularly relevant for those who obtained ZBIO securities through the company's initial public offering (IPO) in September 2024.

Background of the Case

The class action lawsuit revolves around allegations of misleading statements and omissions made by Zenas BioPharma's management. According to the filed complaint, the company significantly overstated its financial stability. It is claimed that the defendants provided false assurances regarding the timeline for sustaining the company’s operations based on existing resources and expected IPO proceeds. As a result, important public statements that investors relied upon during this period were materially misleading.

Who Is Affected?

Investors who purchased or obtained Zenas BioPharma securities at any point leading up to the IPO could potentially bear the brunt of the consequences from these misleading representations.
Levi & Korsinsky details the lawsuit as being designed for those who believe they suffered losses due to the actions or negligence of the company.

If you experienced a decline in your investment value during this timeframe, you may be eligible to participate in this class action lawsuit. Notably, the deadline to join is fast approaching on June 16, 2025.

How to Get Involved

To get involved, investors can easily follow the link provided by Levi & Korsinsky to get more information and submit their interest: Zenas BioPharma Class Action Form.
Alternatively, interested parties can reach out to attorney Joseph E. Levi via email at [email protected] or by phone at (212) 363-7500.

No Financial Obligation

It’s important to emphasize that for those who qualify as class members, participating in the lawsuit comes at no out-of-pocket expense. There are no fees or costs required to join the action, eliminating any financial barriers which might hinder participation.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has built a strong reputation over the years, having successfully recouped millions for distressed investors. With over two decades of experience in handling complex securities litigation, the firm has established itself as a leader in the field. The team of lawyers, which currently comprises more than 70 legal professionals, is known for its expertise and successful track record.
For seven consecutive years, the firm has been recognized in the ISS Securities Class Action Services' Top 50 Report, affirming its committed position among top securities litigation firms in the U.S.

Contact Information

For further inquiries, reach out to:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Website: www.zlk.com

Conclusion

If you feel you have been negatively impacted by your investment in Zenas BioPharma, this class action presents an opportunity for recovery. With a clear deadline of June 16, 2025, it is essential for concerned investors to act swiftly and secure their participation in this important legal action.